We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Asterand Announces Extension of Agreement with Bristol-Myers Squibb
News

Asterand Announces Extension of Agreement with Bristol-Myers Squibb

Asterand Announces Extension of Agreement with Bristol-Myers Squibb
News

Asterand Announces Extension of Agreement with Bristol-Myers Squibb

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Asterand Announces Extension of Agreement with Bristol-Myers Squibb"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Asterand plc has announced that it has extended its collaboration with Bristol-Myers Squibb Company for access to Asterand's products and services for up to three years.

The agreement will focus on access to Asterand's PhaseZERO® drug discovery services and Asterand's XpressBANK™ of human tissue and clinical samples for the continued validation of early drug targets and support for compound optimization.

Asterand CEO Martyn Coombs commented: “This decision by Bristol-Myers Squibb is an important validation of Asterand's products and services. Asterand provides human based solutions that improve decision making during the development of medicines. Our customers incorporate human tissue-based models at all stages of development from target identification to pre-clinical research. We are delighted that Bristol-Myers Squibb has renewed our collaboration and our team looks forward to continuing to support their target validation and compound optimization programmes.”

Under the extended collaboration, Asterand will continue to undertake a range of PhaseZERO® studies for Bristol-Myers Squibb in the areas of compound profiling and target validation. PhaseZERO® studies include gene and protein expression profiling and cellbased pharmacology assays. Likewise, Bristol-Myers Squibb will be granted access to Asterand's XpressBANK™ of human tissue, bio-fluid, and cell lines and may also utilize Asterand's ProCURE™ custom clinical sample collection service.
Advertisement